SK283071B6 - Proteín Deltap62, jeho varianty, nukleotidové sekvencie a ich využitie - Google Patents

Proteín Deltap62, jeho varianty, nukleotidové sekvencie a ich využitie Download PDF

Info

Publication number
SK283071B6
SK283071B6 SK1613-97A SK161397A SK283071B6 SK 283071 B6 SK283071 B6 SK 283071B6 SK 161397 A SK161397 A SK 161397A SK 283071 B6 SK283071 B6 SK 283071B6
Authority
SK
Slovakia
Prior art keywords
nucleic acid
vector
polypeptide
seq
protein
Prior art date
Application number
SK1613-97A
Other languages
English (en)
Slovak (sk)
Other versions
SK161397A3 (en
Inventor
Fabien Schweighoffer
Bruno Tocque
Original Assignee
Rhone-Poulenc Rorer S. A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone-Poulenc Rorer S. A. filed Critical Rhone-Poulenc Rorer S. A.
Publication of SK161397A3 publication Critical patent/SK161397A3/sk
Publication of SK283071B6 publication Critical patent/SK283071B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SK1613-97A 1995-06-01 1996-05-29 Proteín Deltap62, jeho varianty, nukleotidové sekvencie a ich využitie SK283071B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9506533A FR2734826B1 (fr) 1995-06-01 1995-06-01 Deltap62, ses variants, sequences nucleiques et leurs utilisations
PCT/FR1996/000802 WO1996038556A2 (fr) 1995-06-01 1996-05-29 Deltap62, ses variants, sequences d'acides nucleiques les codant, et leurs utilisations en therapie genique anti-cancereuse

Publications (2)

Publication Number Publication Date
SK161397A3 SK161397A3 (en) 1998-07-08
SK283071B6 true SK283071B6 (sk) 2003-02-04

Family

ID=9479588

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1613-97A SK283071B6 (sk) 1995-06-01 1996-05-29 Proteín Deltap62, jeho varianty, nukleotidové sekvencie a ich využitie

Country Status (15)

Country Link
US (1) US6544948B1 (fr)
EP (1) EP0828832A2 (fr)
JP (1) JPH11506325A (fr)
KR (1) KR19990022193A (fr)
AU (1) AU718889B2 (fr)
BR (1) BR9608632A (fr)
CA (1) CA2219861A1 (fr)
CZ (1) CZ291533B6 (fr)
FR (1) FR2734826B1 (fr)
HU (1) HUP9901346A3 (fr)
IL (1) IL118493A0 (fr)
NO (1) NO975409D0 (fr)
SK (1) SK283071B6 (fr)
WO (1) WO1996038556A2 (fr)
ZA (1) ZA964392B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000040606A2 (fr) * 1999-01-06 2000-07-13 The Regents Of The University Of California Modulation de la replication du vih par l'utilisation de sam68
US7479368B2 (en) * 2001-07-30 2009-01-20 G.R.M.O. (Groupe De Recherche En Maladies Osseuses) Inc. Method for detecting subjects having Paget's disease of bone
AU2012294454B2 (en) * 2011-08-08 2017-02-02 Curelab Oncology, Inc. Methods and compositions relating to p62 for the treatment and prophylaxis of cancer
WO2021231652A1 (fr) * 2020-05-14 2021-11-18 Curelab Oncology, Inc. Utilisation du plasmide p62 pour traiter ou réduire la gravité d'infections à coronavirus

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5610276A (en) * 1991-05-17 1997-03-11 Chiron Corporation Polypeptides and antibodies derived from GAP associated protein, p62
WO1995002697A1 (fr) * 1993-07-13 1995-01-26 Rhone-Poulenc Rorer S.A. Vecteurs adenoviraux defectifs et utilisation en therapie genique

Also Published As

Publication number Publication date
FR2734826B1 (fr) 1997-07-04
CZ375997A3 (cs) 1998-02-18
AU6129196A (en) 1996-12-18
CZ291533B6 (cs) 2003-03-12
JPH11506325A (ja) 1999-06-08
HUP9901346A3 (en) 2000-10-30
MX9708877A (es) 1998-03-31
ZA964392B (en) 1996-12-09
IL118493A0 (en) 1996-09-12
BR9608632A (pt) 1999-05-04
WO1996038556A2 (fr) 1996-12-05
HUP9901346A2 (hu) 1999-08-30
CA2219861A1 (fr) 1996-12-05
WO1996038556A3 (fr) 1997-01-09
KR19990022193A (ko) 1999-03-25
EP0828832A2 (fr) 1998-03-18
AU718889B2 (en) 2000-04-20
US6544948B1 (en) 2003-04-08
NO975409L (no) 1997-11-25
SK161397A3 (en) 1998-07-08
FR2734826A1 (fr) 1996-12-06
NO975409D0 (no) 1997-11-25

Similar Documents

Publication Publication Date Title
AU722782B2 (en) Antagonists of the oncogenic activity of the MDM2 protein and their use in the treatment of cancers
EP0938553B1 (fr) Adn codant dp-75 et procede d'utilisation
US6238918B1 (en) DNA sequence encoding the tumor suppressor gene ING1
SK286955B6 (sk) Varianty proteínu p53 a ich terapeutické použitie
US7329741B2 (en) Polynucleotides that hybridize to DP-75 and their use
HU226330B1 (en) Anti-p53 single-chain antibody fragments and their uses to produce pharmaceutical compositions
SK283071B6 (sk) Proteín Deltap62, jeho varianty, nukleotidové sekvencie a ich využitie
EP0846761A1 (fr) Nouveau facteur de transcription exprimé dans des cellules en phase cyclique, molécules d'acides nucléiques codant pour ce facteur de transcription et sa régionpromotrice et utilisations de ceux-ci
MXPA97008877A (en) P62, its variants, the nucleic acid sequences that code them, and its use in anti-cancer gene therapy
US6747133B1 (en) Antibodies against the tumor suppressor gene ING1
CA2315275A1 (fr) Proteine regulatrice de p53 appelee rb18a et ses utilisations
MXPA98001407A (en) Antagonists of the oncogenic activity of the mdm2 protein, and its use in the treatment of the cance